Dissolving microneedles: A transdermal drug delivery system for the treatment of rheumatoid arthritis
- 10 January 2025
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 671, 125206
Abstract
No abstract availableKeywords
This publication has 205 references indexed in Scilit:
- Centrifugal Lithography: Self‐Shaping of Polymer Microstructures Encapsulating Biopharmaceutics by Centrifuging Polymer DropsAdvanced Healthcare Materials, 2017
- Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews2017
- Drawing Lithography: Three‐Dimensional Fabrication of an Ultrahigh‐Aspect‐Ratio MicroneedleAdvanced Materials, 2010
- Association of a single‐nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritisArthritis & Rheumatism, 2009
- Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer MicroneedlesAdvanced Materials, 2008
- Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis & Rheumatism, 2006
- A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullinationArthritis & Rheumatism, 2005
- Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004
- Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twinsArthritis & Rheumatism, 2000
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987